Delayed bedtime sleep restriction for Obesity

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Obesity
Delayed bedtime sleep restriction - Behavioral
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the effects of sleep restriction on energy intake and expenditure.

Treatment Effectiveness

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 24 hour

24 hour
dietary intake
24 hours
physical activity

Trial Safety

Trial Design

3 Treatment Groups

delayed bedtime sleep restriction
1 of 3
early waking sleep restriction
1 of 3
normal sleep
1 of 3

Experimental Treatment

Non-Treatment Group

20 Total Participants · 3 Treatment Groups

Primary Treatment: Delayed bedtime sleep restriction · Has Placebo Group · N/A

delayed bedtime sleep restrictionExperimental Group · 2 Interventions: Early wake sleep restriction, Delayed bedtime sleep restriction · Intervention Types: Behavioral, Behavioral
early waking sleep restrictionExperimental Group · 2 Interventions: Early wake sleep restriction, Delayed bedtime sleep restriction · Intervention Types: Behavioral, Behavioral
normal sleepPlaceboComparator Group · 2 Interventions: Early wake sleep restriction, Delayed bedtime sleep restriction · Intervention Types: Behavioral, Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 hour

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor
327 Previous Clinical Trials
601,106 Total Patients Enrolled
17 Trials studying Obesity
1,893 Patients Enrolled for Obesity
Jill Kanaley, PhDPrincipal InvestigatorUniversity of Missouri-Columbia
6 Previous Clinical Trials
282 Total Patients Enrolled
1 Trials studying Obesity
20 Patients Enrolled for Obesity

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: November 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.